340 related articles for article (PubMed ID: 25418426)
1. Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach.
Berger M; Allen JA
Muscle Nerve; 2015 Mar; 51(3):315-26. PubMed ID: 25418426
[TBL] [Abstract][Full Text] [Related]
2. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies.
Lehmann HC; Hartung HP
J Neuroimmunol; 2011 Feb; 231(1-2):61-9. PubMed ID: 21056913
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin for multifocal motor neuropathy.
Keddie S; Eftimov F; van den Berg LH; Brassington R; de Haan RJ; van Schaik IN
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD004429. PubMed ID: 35015296
[TBL] [Abstract][Full Text] [Related]
4. [Intravenous immunoglobulin-induced eczematous eruption in autoimmune neuromuscular diseases].
Hatake S; Shimizu F; Honda M; Takahashi S; Koga M; Kimura K; Kanda T
Rinsho Shinkeigaku; 2022 Apr; 62(4):267-271. PubMed ID: 35354723
[TBL] [Abstract][Full Text] [Related]
5. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
Markvardsen LH; Christiansen I; Jakobsen J
Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
[TBL] [Abstract][Full Text] [Related]
6. Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.
Dalakas MC
Neurotherapeutics; 2021 Oct; 18(4):2397-2418. PubMed ID: 34766257
[TBL] [Abstract][Full Text] [Related]
7. Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies.
Berger M; McCallus DE; Lin CS
J Peripher Nerv Syst; 2013 Dec; 18(4):275-96. PubMed ID: 24200120
[TBL] [Abstract][Full Text] [Related]
8. Dramatic clinical response to ultra-high dose IVIg in otherwise treatment resistant inflammatory neuropathies.
Kapoor M; Reilly MM; Manji H; Lunn MP; Aisling S ; Carr
Int J Neurosci; 2022 Apr; 132(4):352-361. PubMed ID: 32842835
[TBL] [Abstract][Full Text] [Related]
9. 7(th) International Immunoglobulin Conference: Poster presentations.
Warnatz K; Ballow M; Stangel M; Bril V
Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):139-40. PubMed ID: 25546796
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
11. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
Broyles R; Rodden L; Riley P; Berger M
Postgrad Med; 2013 Mar; 125(2):65-72. PubMed ID: 23816772
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy.
Vlam L; Cats EA; Willemse E; Franssen H; Medic J; Piepers S; Veldink JH; van den Berg LH; van der Pol WL
J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1145-8. PubMed ID: 24336791
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.
Racosta JM; Sposato LA; Kimpinski K
Muscle Nerve; 2017 Jun; 55(6):802-809. PubMed ID: 27649063
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and patient satisfaction in the use of subcutaneous immunoglobulin immunotherapy for the treatment of auto-immune neuromuscular diseases.
Sala TP; Crave JC; Duracinsky M; Lepira Bompeka F; Tadmouri A; Chassany O; Cherin P
Autoimmun Rev; 2018 Sep; 17(9):873-881. PubMed ID: 30005853
[TBL] [Abstract][Full Text] [Related]
15. Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies.
Mathey EK; Garg N; Park SB; Nguyen T; Baker S; Yuki N; Yiannikas C; Lin CS; Spies JM; Ghaoui R; Barnett MH; Vucic S; Pollard JD; Kiernan MC
J Neuroimmunol; 2017 Aug; 309():41-46. PubMed ID: 28601286
[TBL] [Abstract][Full Text] [Related]
16. Intravenous and subcutaneous immunoglobulin G replacement therapy.
Bonilla FA
Allergy Asthma Proc; 2016 Nov; 37(6):426-431. PubMed ID: 27931296
[TBL] [Abstract][Full Text] [Related]
17. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study.
Misbah SA; Baumann A; Fazio R; Dacci P; Schmidt DS; Burton J; Sturzenegger M
J Peripher Nerv Syst; 2011 Jun; 16(2):92-7. PubMed ID: 21692906
[TBL] [Abstract][Full Text] [Related]
18. [Autoantibodies in Chronic Inflammatory Neuropathies].
Yamasaki R
Brain Nerve; 2016 Dec; 68(12):1415-1421. PubMed ID: 27916751
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Tolerability of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Neurologic Diseases.
Chen Y; Wang C; Xu F; Ming F; Zhang H
Clin Ther; 2019 Oct; 41(10):2112-2136. PubMed ID: 31445679
[TBL] [Abstract][Full Text] [Related]
20. Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP.
van Doorn PA; Kuitwaard K; Jacobs BC
J Peripher Nerv Syst; 2011 Jun; 16 Suppl 1():38-40. PubMed ID: 21696496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
